BS_3P20Q2C3
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- age_years
- 6.91
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.294
- SPERMATOGENESIS+0.232
- HEDGEHOG_SIGNALING+0.152
- PANCREAS_BETA_CELLS+0.122
- APICAL_SURFACE+0.015
- APICAL_JUNCTION-0.018
- MYOGENESIS-0.021
- MITOTIC_SPINDLE-0.041
- UV_RESPONSE_DN-0.091
- WNT_BETA_CATENIN_SIGNALING-0.115
Top 10 suppressed
- MYC_TARGETS_V2-0.589
- MYC_TARGETS_V1-0.556
- IL6_JAK_STAT3_SIGNALING-0.553
- E2F_TARGETS-0.502
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.477
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.473
- INTERFERON_ALPHA_RESPONSE-0.473
- UNFOLDED_PROTEIN_RESPONSE-0.472
- DNA_REPAIR-0.461
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0Y66ZBWE | low-grade glioma | — | 0.964 |
| 2 | SRR1478032 | GTEX | — | 0.952 |
| 3 | BS_90B22NGP | ATRT | — | 0.951 |
| 4 | SRR1404640 | GTEX | — | 0.951 |
| 5 | BS_52MPKTJH | high-grade glioma | — | 0.949 |
| 6 | SRR1445149 | GTEX | — | 0.941 |
| 7 | SRR1334717 | GTEX | — | 0.940 |
| 8 | BS_FEPRNEXX | Embryonal tumors | — | 0.939 |
| 9 | MNG700 | — | — | 0.937 |
| 10 | BS_YMAJC22S | low-grade glioma | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.294 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.232 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.152 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.122 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.015 | Temsirolimus | — uncovered |